Stay updated with breaking news from Median dor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Claire Roddie, MD, PhD, presents data from the pooled analysis of the ongoing FELIX phase Ib/II study investigating obecabtagene autoleucel in patients with relapsed/refractory adult B-cell acute lymphoblastic leukemia.
HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
HUTCHMED Announces that it has Completed Enrollment of a globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
ROCKVILLE, Md. and SUZHOU, China, Nov. 30, 2023 /PRNewswire/ -- Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with an HR of 0.64. 2. Grade 3 or 4 treatment-related adverse events occurred in 45.9% in the erdafitinib group and 46.4% in the chemotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Cisplatin-based chemotherapy and
1. The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-related adverse events were similar between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Genomic instability plays a crucial role in the development of small cell lung cancer (SCLC), and replication
1. The progression-free survival was 24.8 months in the selpercatinib group vs 11.2 months in the control group (chemotherapy ± pembrolizumab), with an HR of 0.46. 2. Grade ≥3 adverse events occurred in 70% vs 57% respectively, with elevations in liver enzymes, hypertension, diarrhea, edema, and prolonged QTc occurring more in the selpercatinib group. Evidence
1 .The progression-free survival in berzosertib with topotecan vs topotecan alone was not statistically significant, but the overall survival was significant. 2. Grade ≥3 treatment-related adverse events were similar between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Genomic instability plays a crucial role in the development of small cell lung cancer (SCLC), and
In many countries, trastuzumab deruxtecan is the only HER2-targeted therapy approved for patients with this HER2–mutant metastatic non-small cell lung cancer.